Menu
On January 16, 2026, the United States Supreme Court agreed to hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (No. 24-889),1 a case that will directly shape the future of generic drug competition and the scope of induced patent infringement liability. For pharmaceutical companies, patent practitioners, and healthcare stakeholders alike, this case presents one of the most consequential intersections of patent law and drug regulation in recent memory.
At its core, the case asks how far the doctrine of induced patent infringement extends when a generic manufacturer complies fully with the Food and Drug Administration’s (“FDA’s”) skinny-label pathway but makes routine marketing statements describing its product as a generic equivalent of the branded drug. The Court’s answer will either reaffirm the Section viii carve-out as a meaningful avenue for generic entry, and preserve the Hatch-Waxman Act’s careful balance between innovation and competition, or expose generic manufacturers to patent liability based on ordinary business communications, effectively rendering the skinny-label pathway too risky to use.
Oral argument is scheduled for April 29, 2026, which is the last day of the Court’s April argument session, with a decision expected before the Court’s summer recess.2 Merits briefing is now complete, and stakeholders across the pharmaceutical industry should understand the legal landscape, the competing arguments, and what each possible outcome would mean for drug pricing, patent enforcement, and innovation policy.
To appreciate the stakes of Hikma v. Amarin, the regulatory and legal architecture that gives rise to skinny labels is provided.
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, created a pathway for generic drug manufacturers to seek FDA approval through an Abbreviated New Drug Application (“ANDA”).3 Under 21 U.S.C. § 355(j)(2)(A)(viii), known as the “Section viii carve-out” or “Section viii statement,” a generic applicant may omit from its label a patented method of use that applies to the branded drug, provided the generic’s labeling does not reference that specific indication. The result is a “skinny label” that is approved for fewer uses than the branded reference drug, with the patented indications deliberately removed.
This mechanism has been a cornerstone of generic drug entry. Studies have found that skinny labels were used at launch for nearly half of all first generic small molecule drugs between 2015 and 2019.4 The pathway was designed by Congress to strike a careful balance between protecting an innovator’s patent rights for specific uses while allowing generic competition for off-patent uses, ultimately benefiting consumers with lower drug prices.
Even when the FDA approves a skinny label for a generic drug product, the generic does not operate in a regulatory vacuum. Rather, physicians and pharmacists may substitute a skinny-label generic for the branded product, which includes the patented indication, based on the generic’s AB rating (therapeutically equivalent) and general market substitution practices.5 This “market realities” phenomenon has given rise to the theory that generic manufacturers can induce patent infringement through their marketing practices, even when the label itself is silent on the patented use.
Under 35 U.S.C. § 271(b), whoever actively induces infringement of a patent shall be liable as an infringer. Critically, inducement requires specific intent, which the defendant must have known of the patent and actively encouraged the direct infringing acts of others. The question in Hikma v. Amarin is how far this doctrine extends when a generic manufacturer’s public statements, but not its label, are alleged to constitute that active encouragement?
Amarin Pharma Inc. (“Amarin”) markets Vascepa (icosapent ethyl), a prescription omega-3 fatty acid product. The FDA approved Vascepa in 2012 for the treatment of severe hypertriglyceridemia (the “SH indication”) for patients with blood triglyceride levels of at least 500 mg/dL.6 In 2019, Amarin obtained a supplemental FDA approval for a second, more commercially valuable indication of reducing cardiovascular risk in certain patients with elevated triglycerides (the “CV indication”).7 By 2020, over 90 percent of Vascepa’s sales were attributable to the patented CV indication. Amarin promptly listed method-of-use patents covering the CV indication in FDA’s Orange Book.
Hikma submitted an ANDA in 2016 and, in 2019, filed a Section viii statement carving out the CV indication.8 The FDA approved Hikma’s generic icosapent ethyl product with labeling limited to the SH indication only. Hikma launched its generic with this skinny label, omitting any reference to Amarin’s CV indication.
Despite Hikma’s carve-out, Amarin filed suit in 2020 alleging induced infringement, pointing not to the label itself, but to Hikma’s external communications.9 Specifically, Amarin alleged:
Amarin argued that these communications instructed physicians to prescribe the generic for the patented CV indication, thereby inducing infringement.10
Judge Richard G. Andrews in the District of Delaware dismissed Amarin’s complaint at the pleadings stage, concluding that the allegations were insufficient to state a claim for induced infringement.11 The court found that Hikma’s generic-equivalence statements and investor communications might be relevant to intent, but did not rise to the level of actual inducement by actively encouraging doctors to prescribe for the patented cardiovascular use.12
This decision was in contrast to the Federal Circuit’s decision in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc. (“GSK”), which illustrates the limits of the skinny-label defense.13 There, the court affirmed a jury finding of induced infringement, concluding that Teva’s purported carve-out had failed to actually exclude the patented use from its label, and that a label which retains a patented use is, by definition, “not a skinny label.”14
In 2024, the Federal Circuit reversed, thereby reviving Amarin’s claims.15 Applying its prior precedent from GSK, the Federal Circuit held that courts must evaluate the “totality of the allegations” to determine whether inducement is plausibly pled.16 Crucially, the court held that even if the skinny label alone may not encourage any infringing use, Amarin’s complaint plausibly alleged inducement when the label was considered alongside the non-label marketing materials.17 The Federal Circuit denied rehearing, and Hikma petitioned the Supreme Court.
The Supreme Court granted certiorari on January 16, 2026, making Hikma v. Amarin likely the only patent case granted for argument this term. In a February 2026 amicus brief filed at the Court’s invitation, the Solicitor General urged the Court to grant review and reverse the Federal Circuit, arguing that the lower court’s approach threatens to undermine Congress’s purpose in creating the skinny-label pathway.18 Merits briefing has since concluded as Amarin filed its response brief on March 20, 2026, and Hikma filed its reply brief on April 13, 2026.19,20 Oral arguments are scheduled for April 29, 2026, with a decision expected before the Court’s summer recess.21
In a significant procedural development, the Supreme Court granted the Solicitor General’s motion for leave to participate in oral argument as amicus curiae and for divided argument.22 This means the government will have its own time at the podium on April 29, and not merely a filed brief, which underscores the United States’ active role siding with Hikma and further signaling the case’s importance to federal drug regulatory policy.
Hikma presented two legal questions for the Court’s review23:
1. When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a “generic version” and cites public information about the branded drug (e.g., sales) sufficient to plead induced infringement of the patented use?
2. Does a complaint state a claim for induced infringement of a patented method if it does not allege any instruction or other statement by the defendant that encourages, or even mentions, the patented use?
These questions ask how far induced infringement reaches and whether it covers only explicit encouragement to infringe, or does it also sweep in routine market communications that describe a generic as equivalent to the branded product?
Hikma argues that the Federal Circuit’s approach conflicts with both the text of the Hatch-Waxman Act and established Supreme Court precedent on inducement.24 Under MGM Studios, Inc. v. Grokster, Ltd. (2005), induced infringement requires proof that a defendant took “active steps . . . to encourage direct infringement, such as advertising an infringing use or instructing how to engage in an infringing use.”25 Hikma contends that generic-equivalence statements and references to aggregate sales figures, which are communications that never mention the patented CV indication, simply cannot constitute the active encouragement that Grokster requires.26
Hikma further argues that the Federal Circuit’s standard, which considers the full body of a defendant’s conduct and communications, effectively nullifies the Section viii carve-out.27 If complying with the FDA’s approved label process is insufficient to insulate a generic manufacturer from inducement claims based on ordinary business communications, the skinny-label pathway loses its practical value.28 Generic manufacturers would face an impossible choice: either forgo the Section viii pathway altogether, or limit their communications so severely that their products cannot compete in the marketplace.
In its reply brief filed on April 13, 2026, Hikma pushed back on Amarin’s merits arguments, characterizing them as relying on “strawman assertions” that misrepresent Hikma’s legal position.29
Amarin counters that Hikma is not seeking a legal ruling but is seeking fact-bound error correction, and the Federal Circuit simply applied well-settled inducement doctrine to detailed factual allegations.30 Amarin maintains that a skinny label does not confer blanket immunity from inducement liability, but rather it shifts the focus from the label to the manufacturer’s overall marketing strategy.31 When a generic company affirmatively describes its product as the “generic version” of a drug that is overwhelmingly prescribed for a patented indication, it cannot hide behind label carve-outs to escape liability for the foreseeable consequences of its own statements.32
Amarin also argues that generic manufacturers remain free to avoid liability through more precise marketing, by clearly limiting their promotional communications to the non-patented indication. In Amarin’s view, Hikma could have avoided this litigation simply by distinguishing its product from the full Vascepa brand in its investor communications and press releases.33
Amarin further contends that “Petitioners’ arguments, if accepted, would dramatically dilute intellectual property protection throughout the Nation by shielding intentional efforts to use crafty statements to encourage infringing copycat sales.”34
Notably, in its March 20 merits brief, Amarin also urged the Court to dismiss the writ of certiorari as improvidently granted, arguing that Hikma had abandoned positions it staked at the certiorari stage, including contentions regarding pre-Twombly pleading standards and whether inducement is a question of law or fact.35 Amarin further noted that fact discovery since the Federal Circuit mandate has uncovered additional evidence of intentionally induced infringement.36
Former Congressman Henry A. Waxman, the co-author of the Hatch-Waxman Act, filed an amicus brief urging the Supreme Court to reverse the Federal Circuit.37 Waxman argues that the Federal Circuit’s decision is “flatly inconsistent” with both the text of the Act and congressional intent, and that unless overturned it will “devastate” the generic drug program that has saved patients and payers trillions of dollars.38 Waxman emphasizes that Congress specifically anticipated the scenario at issue, i.e., a brand obtaining a new use patent years after a generic had already entered for the original indication, and deliberately created the Section viii carve-out pathway to address it.39 In his view, the Federal Circuit’s approach renders that pathway meaningless, because it permits brand companies to allege induced infringement based on routine generic-equivalence statements and investor communications that have been standard industry practice since Hatch-Waxman’s enactment.40 Waxman further warns that without clear guidance on how to avoid liability, financially constrained generic manufacturers will simply forgo skinny-label launches altogether, the precise opposite of what Congress intended.41
A brief filed by 76 scholars of law, medicine, economics, and business added further empirical weight to Hikma’s position.42 The scholars argued that the Federal Circuit’s approach creates an impossible double-bind in that generic manufacturers are legally required to mirror the brand label, yet that same mandatory labeling was used as evidence of inducement against Hikma.43 The scholars also provided empirical data showing that skinny-label use dropped from roughly 40-50% of first generic approvals between 2015 and 2022 to just 20% in 2023, which is a decline they attribute directly to the Federal Circuit’s GSK decision, and that only 15 skinny-label drugs saved Medicare Part D $14.6 billion between 2015 and 2021.44 The scholars warned that an expanded inducement doctrine would further prevent innovation incentives, encouraging brand manufacturers to pursue cheap, low-value method-of-use patents as competitive weapons rather than investing in genuine research.45 Notably, even the FDA sought a legislative fix in its 2024 budget proposal, asking Congress to create a safe harbor for skinny labels and warning that GSK “imperils an important statutory marketing pathway.”46
AbbVie Inc. and Bristol-Myers Squibb Company filed an amicus brief in support of Amarin, arguing that this case presents a straightforward application of established inducement doctrine, not a threat to the skinny-label pathway.47 Their central contention is that Hikma knew approximately 75% of its product’s real-world uses were infringing, yet took no steps to warn wholesalers, pharmacies, or insurers.48 Drawing on Metro-Goldwyn-Mayer Studios Inc. v. Grokster, Ltd., the brief argues that knowingly profiting from pervasive, systemic infringement while failing to mitigate it constitutes active inducement.49 The brief also draws a pointed contrast with the Supreme Court’s recent decision in Cox Communications, Inc. v. Sony Music Entertainment, emphasizing that unlike Cox, Hikma implemented no warnings, no contractual prohibitions, and no remediation measures whatsoever.50 AbbVie and BMS further contend that other countries, including the United Kingdom in the Lyrica pregabalin litigation, have required generic manufacturers to take affirmative steps to confine their products to approved, non-infringing indications.51
Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, and Johns Hopkins University School of Medicine filed an amicus brief in support of Amarin, arguing that the Hatch-Waxman Act’s careful balance between innovation and generic access has eroded to the point where investment in new uses of existing drugs is no longer viable.52 As a concrete example, the brief notes that metformin, which was approved for diabetes in 1995, shows promise as a cancer treatment, yet no company will fund the necessary clinical trials because section viii carve-outs undermine the ability to recoup that investment.53 The brief introduces a critical structural argument absent from the other pro-Amarin submissions: in the payer-driven pharmaceutical market, generic substitution is controlled primarily by pharmacy benefit managers, meaning inducement occurs through private contracts that only discovery can uncover.54 The amicus brief takes a deliberately narrow procedural posture, arguing not that Hikma definitively induced infringement, but that dismissal before discovery would permanently foreclose that determination.55
A ruling in Hikma’s favor would reaffirm the Section viii pathway as a meaningful avenue for generic competition and provide clearer standards for generic marketing communications. Generic manufacturers could rely on their FDA-approved carve-out labels as meaningful shields, provided their external communications do not affirmatively reference or promote the patented indication. A decision tightening inducement standards could support earlier generic entry, reduce litigation risk, and ultimately lower drug prices for consumers.
Alternatively, a ruling for Amarin would impose significant compliance burdens on generic manufacturers. Companies would need to scrutinize every investor presentation, press release, and marketing communication for any language that could be construed as encouraging the patented use, even indirectly. Skinny label launches would require legal review of all public communications, and even then, the risk of litigation may remain difficult to calculate.
A ruling for Amarin could restore meaningful value to method-of-use patents in an era when skinny labels have eroded the practical scope of those patents post-ANDA approval. Innovators would have greater ability to enforce their patent rights against generics whose market positioning reads on the patented use, even without direct label infringement.
However, the Solicitor General warned that even the threat of discovery under the Federal Circuit’s standard could chill skinny-label use and delay lower-cost drugs from reaching patients, which underscores the public health dimension of this legal dispute.56
Legal commentators have noted that the Court’s resolution will likely shape inducement liability doctrine beyond the pharmaceutical context. Because it appears that the Court will decide the case on general inducement principles rather than by crafting a rule that is specific to pharmaceutical companies, the decision could redefine what pleadings must be alleged to state a claim for inducement across all patent-heavy industries, including software, electronics, and life sciences.
Until the Supreme Court issues its decision, generic manufacturers should perform comprehensive reviews of all marketing materials, press releases, investor communications, and website content associated with skinny-label products. Where a drug’s dominant commercial use is the patented indication, any generalized equivalence statements carry elevated risk under the current Federal Circuit standard. Legal counsel should be involved in drafting communications that contextualize the scope of the generic approval.
Innovators with method-of-use patents should monitor their generic competitors’ public communications and investor disclosures as a component of ongoing patent enforcement strategy. The Federal Circuit’s current standard provides meaningful opportunities to plead inducement claims based on the totality of a generic’s market positioning, but the Supreme Court may narrow or clarify that standard. Enforcement strategies should be developed with an eye toward the range of possible outcomes in Hikma.
The case has significant implications for how method-of-use patents are valued, licensed, and litigated. Counsel advising on ANDA litigation, Paragraph IV certifications, and post-launch patent enforcement should closely monitor the oral argument, which is scheduled for April 29, 2026, and any subsequent opinions for signals about the Court’s direction. The decision may also prompt reconsideration of how method-of-use patents are drafted and prosecuted to maximize enforceability against skinny-label generics.
Hikma v. Amarin arrives at the Supreme Court at a critical moment for pharmaceutical competition policy. The case forces the Court to resolve a genuine tension at the heart of the Hatch-Waxman framework by which Congress created the skinny-label pathway to facilitate generic competition, yet induced infringement doctrine exists to protect innovators from having their patents rendered commercially meaningless. Neither party’s position is without merit, and the Court’s resolution will require it to draw principled lines about what it means to “actively induce” infringement in an era of sophisticated pharmaceutical marketing.
Since the article was originally drafted, the litigation landscape has advanced materially. Merits briefing is now complete, the Solicitor General has secured time at the podium for divided argument on April 29, Amarin has raised a threshold DIG challenge to the grant of certiorari, and Hikma has responded by characterizing Amarin’s arguments as strawman attacks. The decision will almost certainly be one of the most closely watched patent law rulings of the decade not only for what it says about skinny labels, but for what it reveals about the Court’s broader vision of inducement liability. Stakeholders across the pharmaceutical supply chain should be prepared for a ruling in the coming months.